Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F B Wright

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
BMJ Open|August 3, 2024
Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study)Lisa Stamp, Leanne Te Karu, Susan Reid, et al.
Clinical Pharmacokinetics|July 28, 2025
The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective DosingDaniel F B Wright, Hailemichael Z Hishe, Nicola Dalbeth, et al.
British Journal of Clinical Pharmacology|February 16, 2020
The pharmacokinetics of metformin in patients receiving intermittent haemodialysisKlarissa A Sinnappah, Isabelle H S Kuan, Tilenka R J Thynne, et al.
British Journal of Clinical Pharmacology|July 27, 2023
A framework for understanding sources of bias in medication adherence researchKlarissa A Sinnappah, Dyfrig A Hughes, Sophie L Stocker, et al.
British Journal of Clinical Pharmacology|February 21, 2024
Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosingMarcel Schulz, Matthew J Coleshill, Richard O Day, et al.
European Journal of Clinical Pharmacology|March 12, 2013
The population pharmacokinetics of allopurinol and oxypurinol in patients with goutDaniel F B Wright, Lisa K Stamp, Tony R Merriman, et al.
Journal of Nephrology|March 25, 2025
Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping reviewNoha A Kamel, Michael A Stokes, Daniel F B Wright, et al.
Seminars in Arthritis and Rheumatism|June 14, 2014
Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of goutLisa K Stamp, Tony R Merriman, Murray L Barclay, et al.
Clinical Pharmacokinetics|December 13, 2016
A Population Pharmacokinetic Model for <sup>51</sup>Cr EDTA to Estimate Renal FunctionIsabelle H S Kuan, Stephen B Duffull, Tracey L Putt, et al.
Clinical and Translational Science|November 18, 2022
The impact of genetic variability in urate transporters on oxypurinol pharmacokineticsHailemichael Z Hishe, Sophie L Stocker, Lisa K Stamp, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
BMJ Open|August 3, 2024
Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study)Lisa Stamp, Leanne Te Karu, Susan Reid, et al.
Clinical Pharmacokinetics|July 28, 2025
The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective DosingDaniel F B Wright, Hailemichael Z Hishe, Nicola Dalbeth, et al.
British Journal of Clinical Pharmacology|February 16, 2020
The pharmacokinetics of metformin in patients receiving intermittent haemodialysisKlarissa A Sinnappah, Isabelle H S Kuan, Tilenka R J Thynne, et al.
British Journal of Clinical Pharmacology|July 27, 2023
A framework for understanding sources of bias in medication adherence researchKlarissa A Sinnappah, Dyfrig A Hughes, Sophie L Stocker, et al.
British Journal of Clinical Pharmacology|February 21, 2024
Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosingMarcel Schulz, Matthew J Coleshill, Richard O Day, et al.
European Journal of Clinical Pharmacology|March 12, 2013
The population pharmacokinetics of allopurinol and oxypurinol in patients with goutDaniel F B Wright, Lisa K Stamp, Tony R Merriman, et al.
Journal of Nephrology|March 25, 2025
Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping reviewNoha A Kamel, Michael A Stokes, Daniel F B Wright, et al.
Seminars in Arthritis and Rheumatism|June 14, 2014
Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of goutLisa K Stamp, Tony R Merriman, Murray L Barclay, et al.
Clinical Pharmacokinetics|December 13, 2016
A Population Pharmacokinetic Model for <sup>51</sup>Cr EDTA to Estimate Renal FunctionIsabelle H S Kuan, Stephen B Duffull, Tracey L Putt, et al.
Clinical and Translational Science|November 18, 2022
The impact of genetic variability in urate transporters on oxypurinol pharmacokineticsHailemichael Z Hishe, Sophie L Stocker, Lisa K Stamp, et al.
Pageof 8